Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$196.82 USD

196.82
2,946,862

-0.14 (-0.07%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Arpita Dutt headshot

Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi

While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.

    Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance

    Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.

      Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View

      Anthem (ANTM) reported strong fourth-quarter results on the back of solid performance across its segments.

        The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton

        The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton

          Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX

          Two pharma/biotech giants are scheduled to report earnings on Jan 31. Let's take a look at how the companies are placed ahead of the upcoming releases.

            HCA Healthcare's (HCA) Q4 Earnings, Revenues Beat Estimates (Revised)

            HCA Healthcare's (HCA) strong fourth-quarter results were driven by significant growth in admissions.

              Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors

              Novartis' oncology portfolio gets a further boost with the FDA approval of Lutathera for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.

                Roche Hemophilia Drug Hemlibra Gets Positive CHMP Opinion

                Roche announced that it its hemophilia drug Hemlibra obtained a positive opinion from the Committee for Medicinal Products for Human Use in Europe.

                  AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III

                  AstraZeneca (AZN) announces positive top-line results from the phase III KRONOS study on the triple combination therapy PT010 for severe COPD patients.

                    Stock Market News for Jan 29, 2018

                    All the three key U.S. indexes closed at record levels on Friday following better-than-expected earnings from Intel, AbbVie and Honeywell

                      Strength Seen in AbbVie (ABBV): Stock Soars 13.8%

                      AbbVie (ABBV) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.

                        Arpita Dutt headshot

                        AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call

                        With AbbVie (ABBV) surpassing expectations in the fourth quarter, here's a look at a few important takeaways from the company's conference call.

                          AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up

                          AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.

                            A Spate of Q4 Earnings

                            A Spate of Q4 Earnings

                              Mark Vickery headshot

                              Q4 GDP Sub-3%, Q4 Earnings Roll On

                              The first read for Q4 GDP reached 2.6%, lower than the consensus estimate of 2.9%.

                                AbbVie (ABBV) Q4 Earnings & Revenues Beat, Guidance Raised

                                AbbVie's (ABBV) fourth-quarter 2017 earnings surpassed estimates with revenues marginally beating the same. Sales of its lead marketed drug Humira also increased compared with the year ago figure.

                                  Novartis Gets Spark Therapeutics' Luxterna License Outside US

                                  Novartis has obtained the marketing rights for Luxterna oustide the United States thereby building upon its gene therapy treatments which includes Kymriah.

                                    Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth?

                                    J&J (JNJ) has a history of issuing a cautious outlook, especially at the beginning of the year. However, there are several tailwinds, which can coax it to improve the 2018 projection.

                                      Will Pfizer (PFE) Surpass Estimates This Earnings Season?

                                      While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q4, genericization of key drugs and supply shortages in legacy Hospira products will hurt sales.

                                        Why AbbVie (ABBV) Might Surprise This Earnings Season

                                        AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

                                          Is a Beat in the Cards for AbbVie (ABBV) in Q4 Earnings?

                                          Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q4.

                                            Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto

                                            Novartis (NVS) announced strong results for the fourth quarter as earnings and sales both beat estimates driven by Cosentyx and Entresto sales which more than offset the decline in Gleevec sales.

                                              The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca

                                              The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca

                                                Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?

                                                Stryker's (SYK) robust fundamentals and broad product scale are likely to drive performance in the Q4. However, the company faces product-recall issues.

                                                  Novartis Announces Positive Results on Migraine Candidate

                                                  Novartis announced positive results on migraine candidate, AMG334, from the phase IIIb study. The candidate is being developed in collaboration with Amgen,